ARCHIVES

“The Working Group urges NCI to reconsider its current budget to determine whether the 25 percent devoted to the IRP is appropriate.”

This article is from The Cancer Letter archive.

Vol. 21 No. 27 | July 7, 1995

Download PDF Visit The Full Archive

Related Articles

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

March 30, 2001

TGen At Scottsdale Opens Clinical Trial Of OSI-906 For Adrenocortical Carcinoma

September 25, 2009

FDA Announces Plan to Reform Drug Approval, Hire Outside Experts To Handel Some Reviews

November 22, 1991

ACCC Planning Session Considers Community Impact

August 31, 1979

More Debate Due On Organ Site Program; First Round Reviewed By DRG “Slaughtered”

January 28, 1983

Sledge: Prepare for Genomic Information “Tsunami”

June 10, 2011